Author(s):
A. K. Sadanov, N. N. Gavrilova, I. A. Ratnikova*, S. E. Orazymbet, L.E. Protasiuk, A. D. Massirbaeva
Email(s):
iratnikova@list.ru
DOI:
10.52711/0974-360X.2023.00864 
Address:
A. K. Sadanov, N. N. Gavrilova, I. A. Ratnikova*, S. E. Orazymbet, L.E. Protasiuk, A. D. Massirbaeva
Research and Production Center for Microbiology and Virology, 105 Bogenbai Batyr Str., Almaty, 050010, Kazakhstan.
*Corresponding Author
Published In:
Volume - 16,
Issue - 11,
Year - 2023
ABSTRACT:
The study aims to develop the technology of producing lyophilizate association of lactic acid bacteria included in the AS-Probionorm medicinal product. The association for obtaining the lyophilizate includes the following cultures of microorganisms – Lactobacillus fermentum 30 +Lactobacillus cellobiosus 36. It is found that to obtain a lyophilizate of the association of lactic acid bacteria included in AS-Probionorm, the best medium for cultivation is MRS with CoCl2. The optimal variant of lyophilic drying involves shelf temperature equalization (+20°C) – 5min, freezing (-30°C) – 10h, freezing (-60°C) – 5h, vacuum – 0.2mbar, drying 1(-26°C) – 6h, drying 2(+20°C) – 18h, drying 3(+30°C) – 2h with the entire process lasting at least 26hours and the final product temperature being +(25-27)°C. This procedure produces lyophilizates of the lactic acid bacteria association with high indicators of bacterial viability and antagonistic activity upon drying and after storage. Following the developed technology, the production of this effective probiotic drug against intestinal and associated infections will be established in Kazakhstan for domestic use, as well as for export to other countries.
Cite this article:
A. K. Sadanov, N. N. Gavrilova, I. A. Ratnikova*, S. E. Orazymbet, L.E. Protasiuk, A. D. Massirbaeva. Technology for the production of Lyophilizate of an association of Lactic acid bacteria included in the Medicinal product AS-Probionorm. Research Journal of Pharmacy and Technology. 2023; 16(11):5334-0. doi: 10.52711/0974-360X.2023.00864
Cite(Electronic):
A. K. Sadanov, N. N. Gavrilova, I. A. Ratnikova*, S. E. Orazymbet, L.E. Protasiuk, A. D. Massirbaeva. Technology for the production of Lyophilizate of an association of Lactic acid bacteria included in the Medicinal product AS-Probionorm. Research Journal of Pharmacy and Technology. 2023; 16(11):5334-0. doi: 10.52711/0974-360X.2023.00864 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2023-16-11-58
REFERENCES:
1. World Health Organization. World Health Statistics 2011. World Health Organization, 2011; 170 p.
2. Zabolevaemostnaseleniia Respubliki Kazakhstan v 2019 godu [Morbidity in the Republic of Kazakhstan in 2019].February 19, 2020. Available at: https://www.zakon.kz/5008014-zabolevaemost-naseleniya-respubliki.html
3. Rojas-Lopez M. Monterio R. Pizza M. Desvaux M. Rosini R. Intestinal pathogenic Escherichia coli: Insights for vaccine development. Frontiers in Microbiology. 2018; 9: 440.doi: 10.3389/fmicb.2018.00440
4. Luo Q. Wan F. Yu X. Zheng B. Chen Y. Gong C. Fu H. Xiao Y. Li L. MDR Salmonella enterica serovar Typhimurium ST34 carrying mcr-1 isolated from cases of bloodstream and intestinal infection in children in China.Journal of Antimicrobial Chemotherapy. 2020; 75(1): 92-5.doi: 10.1093/jac/dkz415
5. Joseph L. Merciecca T. Forestier C. Balestrino D. Miquel S. From klebsiella pneumoniae colonization to dissemination: An overview of studies implementing murine models. Microorganisms. 2021; 9(6): 1282.doi: 10.3390/microorganisms9061282
6. Dong D. Ni Q. Wang C. Zhang L. Li Z. Jiang C. Mao E. Peng Y. Effects of intestinal colonization by Clostridium difficile and Staphylococcus aureus on microbiota diversity in healthy individuals in China. BMC Infectious Diseases. 2018; 18(1): 207.doi: 10.1186/s12879-018-3111-z
7. Maraj B. Huang A. Patel S. Acute colitis in a patient with streptococcus pyogenes bacteremia.The American Journal of Medicine. 2018; 131(1):e13-4.doi: 10.1016/j.amjmed.2017.09.022
8. Johnson M. Bartscherer A. Tobin E. Tafen M. Streptococcus pyogenes peritonitis: A rare, lethal imitator of appendicitis. BMJ Case Reports. 2019; 12(9): e230490.doi: 10.1136/bcr-2019-230490
9. Namazova-Baranova LS, Baranov AA. Antibiotic resistance in modern world. Pediatric Pharmacology. 2017; 14(5): 341-54.doi: 10.15690/pf.v14i5.1782
10. Prakash S. Rodes L. Coussa-Charley M. Tomaro-Duchesneau C. Gut microbiota: Next frontier in understanding human health and development of biotherapeutics. Biologics: Targets & Therapy. 2011;5:71-86.doi: 10.2147/BTT.S19099
11. Ianiro G. Bibbò S. Gasbarrini A. Cammarota G. Therapeutic modulation of gut microbiota: Current clinical applications and future perspectives. Current Drug Targets. 2014; 15(8): 762-70. doi: 10.2174/1389450115666140606111402
12. Ushkalova EA.Zyrianov SK. Mesto preparatov, vliiaiushchikhnamikrobiotukishechnika, v sovremennoimeditsine [Place of drugs that affect the intestinal microbiota in modern medicine]. Pediatrics (Suppl. ConsiliumMedicum). 2017; 2:37-42.
13. Sturov NV. Popov SV. Zhukov VA. Modern approaches to the correction of the gut microbiota. Meditsinskiy Sovet. 2021; 4:136-43.doi: 10.21518/2079-701X-2021-4-136-143
14. Hill C. Guarner F. Reid G. Gibson GR. Merenstein DJ. Pot B. Morelli L. Canani RB. Flint HJ. Salminen S. Calder PC. Sanders ME. Expert consensus document: The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic.Nature Reviews Gastroenterology and Hepatology. 2014; 11(8):506-14.doi: 10.1038/nrgastro.2014.66
15. Zhang CX. Wang HY. Chen TX. Interactions between intestinal microflora/probiotics and the immune system. BioMed Research International. 2019; 2019:6764919.doi: 10.1155/2019/6764919
16. Gou HZ. Zhang Y-L. Ren L-F. Li Z-J. Zhang L. How do intestinal probiotics restore the intestinal barrier? Frontiers in Microbiology. 2022; 13: 929346.doi: 10.3389/fmicb.2022.929346
17. Yousefi B. Eslami M. Ghasemian A. Kokhaei P. SalekFarrokhi A. Darabi N. Probiotics importance and their immunomodulatory properties.Journal of Cellular Physiology. 2019; 234(6): 8008-18. doi: 10.1002/jcp.27559
18. Wells JM. Immunomodulatory mechanisms of lactobacilli. Microbial Cell Factories. 2011; 10(Suppl 1): S17. doi: 10.1186/1475-2859-10-S1-S17
19. Daliri EBM. Lee BH. New perspectives on probiotics in health and disease.Food Science and Human Wellness. 2015; 4(2): 56-65. doi: 10.1016/j.fshw.2015.06.002
20. World Gastroenterology Organisation. WGO Global Guidelines. Probiotics and Prebiotics. 2017. Available at: https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-english-2017.pdf
21. Andreeva IV.Stetsiuk OU. Mesto probiotikov v prakticheskikhrekomendatsiiakh po gastroenterologii: Realnostiblizhaishieperspektivy [The place of probiotics in practical recommendations for gastroenterology: Reality and immediate prospects].Consilium Medicum. 2018; 20(8): 67-72.
22. Nikolaeva SV. ZolotarevIu V. Gorelov AV. Primenenieprobiotikov V meditsinskoipraktike [Application of probiotics in medical practice]. Russian Medical Inquiry. 2018; 8(11):84-7.
23. Sebastián Domingo JJ. Revisióndelpapel de los probióticos en la patologíagastrointestinaldeladulto.Gastroenterología y Hepatología. 2017; 40(6):417-29.doi: 10.1016/j.gastrohep. 2016.12.003
24. Lim HJ, Shin HS. Antimicrobial and immunomodulatory effects of bifidobacterium strains: A review.Journal of Microbiology and Biotechnology. 2021; 30(12): 1793-800. doi: 10.4014/jmb.2007.07046
25. Gagliardi A. Totino V. Cacciotti F. Iebba V. Neroni B. Bonfiglio G. Trancassini M. Passariello C. Pantanella F. Schippa S. Rebuilding the gut microbiota ecosystem.International Journal of Environmental Research and Public Health. 2018; 15(8): 1679.doi: 10.3390/ijerph15081679
26. Kumar R. Sood U. Gupta V. Singh M. Scaria J. Lal R. Recent advancements in the development of modern probiotics for restoring human gut microbiome dysbiosis.Indian Journal of Microbiology. 2020; 60(1): 12-25.doi: 10.1007/s12088-019-00808-y
27. do Carmo MS. Santos CID. Araújo MC. Girón JA. Fernandes ES. Monteiro-Neto V. Probiotics, mechanisms of action, and clinical perspectives for diarrhea management in children. Food & Function. 2018; 9(10): 5074-95.doi: 10.1039/c8fo00376a
28. Guo Q. Goldenberg JZ. Humphrey C. El Dib R. Johnston BC. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database of Systematic Reviews. 2019. 4:CD004827.doi: 10.1002/14651858.CD004827.pub5
29. Goldenberg JZ. Ma SS. Saxton JD. Martzen MR. Vandvik PO. Thorlund K. Guyatt GH. Johnston BC. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database of Systematic Reviews. 2013; 5:CD006095.doi: 10.1002/14651858.CD006095.pub3
30. Sniffen JC. McFarland LV. Evans CT. Goldstein EJC. Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. PLoS One. 2018. 13(12): e0209205.doi: 10.1371/journal.pone.0209205
31. Lionetti E. Francavilla R. Castellazzi AM. Arrigo T. Labò E. Leonardi S. Ciprandi G. Miraglia Del Giudice M. Salpietro V. Salpietro C. La Rosa M. Probiotics and Helicobacter pylori infection in children. Journal of Biological Regulators and Homeostatic Agents. 2012; 26(1):69-76.
32. Alfaleh K.Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants.Cochrane Database of Systematic Reviews. 2014. 4:CD005496.doi: 10.1002/14651858.CD005496.pub4
33. Underwood MA. Probiotics and the prevention of necrotizing enterocolitis.Journal of Pediatric Surgery. 2019; 54(3): 405-12.doi: 10.1016/j.jpedsurg.2018.08.055
34. Hudson LE. Anderson SE. Corbett AH. Lamb TJ.Gleaning insights from fecal microbiota transplantation and probiotic studies for the rational design of combination microbial therapies.Clinical Microbiology Reviews. 2017; 30(1):191-231. doi: 10.1128/CMR.00049-16
35. Hajavi J. Esmaeili SA. Varasteh AR. Vazini H. Atabati H. Mardani F. Momtazi-Borojeni AA. Hashemi M. Sankian M. Sahebkar A. The immunomodulatory role of probiotics in allergy therapy.Journal of Cellular Physiology. 2019; 234(3): 2386-98. doi: 10.1002/jcp.27263
36. Sharma G. Im SH. Probiotics as a potential immunomodulating pharmabiotics in allergic diseases: Current status and future prospects.Allergy, Asthma & Immunology Research. 2018; 10(6): 575-90. doi: 10.4168/aair.2018.10.6.575
37. Zajac AE. Adams AS. Turner JH. A systematic review and meta-analysis of probiotics for the treatment of allergic rhinitis.International Forum of Allergy & Rhinology. 2015; 5(6): 524-32. doi: 10.1002/alr.21492
38. Bustamante M. Oomah BD. Oliveira WP. Burgos-Díaz C. Rubilar M. Shene C. Probiotics and prebiotics potential for the care of skin, female urogenital tract, and respiratory tract. Folia Microbiologica. 2020; 65(2): 245-64. doi: 10.1007/s12223-019-00759-3
39. Szajewska H. Urbańska M. Chmielewska A. Weizman Z. Shamir R. Meta-analysis: Lactobacillus reuteri strain DSM 17938 (and the original strain ATCC 55730) for treating acute gastroenteritis in children. Beneficial Microbes. 2014; 5(3): 285-93. doi: 10.3920/BM2013.0056
40. Ouwehand AC. Forssten S. Hibberd AA. Lyra A. Stahl B. Probiotic approach to prevent antibiotic resistance.Annals of Medicine. 2016; 48(4): 246-55. doi: 10.3109/07853890.2016.1161232
41. Korpela K. Salonen A. Virta LJ. Kumpu M. Kekkonen RA. de Vos WM. Lactobacillus rhamnosus GG intake modifies preschool children’s intestinal microbiota, alleviates penicillin-associated changes, and reduces antibiotic use. PLoS One. 2016; 11(4): e0154012.doi: 10.1371/journal.pone.0154012
42. King S. Tancredi D. Lenoir-Wijnkoop I. Gould K. Vann H. Connors G. Sanders ME. Linder JA. Shane AL. Merenstein D. Does probiotic consumption reduce antibiotic utilization for common acute infections? A systematic review and meta-analysis. European Journal of Public Health. 2019; 29(3): 494-9.doi: 10.1093/eurpub/cky185
43. Millette M. Nguyen A. Amine KM. Lacroix M. Gastrointestinal survival of bacteria in commercial probiotic products.International Journal of Probiotics and Prebiotics. 2013; 8(4): 149-56.
44. Toscano M. de Vecchi E. Rodighiero V. Drago L. Microbiological and genetic identification of some probiotics proposed for medical use in 2011. Journal of Chemotherapy. 2013; 25(3): 156-61.doi: 10.1179/1973947812Y.0000000068
45. Egorov NS. Osnovyucheniiaobantibiotikakh [Fundamentals of the study of antibiotics]. MSU Publishing House, Moscow. 1994; 512 p.
46. Lokhande S. More S.Raje V. A Systematic Study of Probiotics- An Update Review. Asian J. Pharm. Tech. 2018; 8(3): 149-157. doi: 10.5958/2231-5713.2018.00024.7
47. Chauhan SB. Singh V. Chauhan R. Enteric coated Microbeads as a Potential Delivery System for improved probiotic effect of Lactobacillus rhamnosus GG. Research J. Pharm. and Tech. 2019; 12(12): 6049-6056. doi: 10.5958/0974-360X.2019.01050.3
48. El-Waseif AA. Gaber HS.Ewais EA. Hypocholesterolemic Operating Parameters of Novel Probiotics In vitro. Research J. Pharm. and Tech. 2021; 14(10): 5197-1. doi: 10.52711/0974-360X.2021.00904
49. El-Waseif AA.Abobaker RA. Abdel-Monem MO. Attia AA. Hassan MG. The Lactobacillus brevis Prebiotic Pure Exo polysaccharide and its Nano crystalline Characterization, anti-colon cancer and cytotoxicity. Research J. Pharm. and Tech. 2021; 14(11): 5998-2. doi: 10.52711/0974-360X.2021.01042
50. Sari EK.Wihastuti TA.Afenia PR.Ardiansyah W. Probiotic can Prevent Sepsis in Rats Induced by Lipopolysaccharide Escherichia coli. Research J. Pharm. and Tech. 2021; 14(12): 6315-0. doi: 10.52711/0974-360X.2021.01092
51. Maharini FS.Amridjati M. Poddar S. Standardization of Growol processing and the effect of different processing processes on the potential of Growol as functional food. Research J. Pharm. and Tech. 2023; 16(2): 615-0. doi: 10.52711/0974-360X.2023.00105
52. Dewi NP. Poddar S. Rai RP.Purwati E. Abdullah D.Pratama YE. The Potential Lactic Acid Bacteria from DadiahSianokBukittinggi City, West Sumatera as Probiotic. Research J. Pharm. and Tech. 2023; 16(2): 627-4. doi: 10.52711/0974-360X.2023.00107
53. Jaleel S.Kiliç AO. Antimicrobial Action of isolated Probiotic Lactobacillus plantarum from Different Fermented Dairy Products from Trabzon City. Research J. Pharm. and Tech. 2020; 13(5): 2445-2451. doi: 10.5958/0974-360X.2020.00438.2
54. Sundaramoorthy S. Selvaraj S.Kameshwari V. Antibacterial Activity of Lactobacillus Species Isolated from Dairy products against Antibiotics. Research J. Pharm. and Tech. 2020; 13(8): 3915-3917. doi: 10.5958/0974-360X.2020.00693.9
55. Nurrosyidah IH.Mertaniasih NM.Isnaeni I. Antibacterial Activity of Probiotics Cell-Free Fermentation Filtrate from Passiflora edulis Sims. againts Pathogen bacteria. Research J. Pharm. and Tech. 2022; 15(12):5767-3. doi: 10.52711/0974-360X.2022.00973
56. Gavrilova NN. Ratnikova IA. Bayakyshova K. Ybysheva SD. TurlybaevaZZh. Increase of antagonistic activity of probiotic microorganisms by additives in the composition of the nutrient medium.In Collection of scientific papers on the materials of the scientific-practical conference “Actual problems of the development of science and education”.Limited Liability Company "AR-Consult", Lyubertsy. 2014; Part 1, 34-41.
57. Romyasamit C. Saengsuwan P. Boonserm P. Thamjarongwong B. Singkhamanan K. Optimization of cryoprotectants for freeze-dried potential probiotic Enterococcus faecalis and evaluation of its storage stability. Drying Technology. 2022; 40(11): 2283-92.doi: 10.1080/07373937.2021.1931294
58. Jawan R. Abbasiliasi S. Tan JS.Kapri MR. Mustafa S. Halim M. Ariff AB. Influence of type and concentration of lyoprotectants, storage temperature and storage duration on cell viability and antibacterial activity of freeze-dried lactic acid bacterium, Lactococcus lactis Gh1. Drying Technology. 2022; 40(9): 1774-90.doi: 10.1080/07373937.2021.1874968